Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

PROLX
80458
FFLUR
90091
17BFP
89739
Fluphenazine (Prolixin), Serum
Reference Values:
Reference Range: 0.5-20 ng/ml
Critical Value: 40.0 ng/ml
Expected range for low dose therapy: 0.5-2.25 ng/ml
Expected range for high dose therapy: 5.0-20.0 ng/ml
Some patients respond well to the lower range of therapy
while other patients require the higher concentrations to
achieve desired therapeutic effects.
Analysis performed by Liquid Chromatography/Tandem
Mass Spectrometry (LC/MS/MS).
TEST PERFORMED BY
MEDTOX LABORATORIES, INC.
402 W. COUNTY ROAD D
ST. PAUL, MN 55112
Flurazepam (Dalmane) and Desalkylflurazepam
Reference Values:
Flurazepam:
Reference Range: 0-30 ng/mL
Desalkylflurazepam:
Reference Range: 30-150 ng/mL
Flurazepam and Desalkyflurazepam:
Reference Range: 30-180 ng/mL
Test Performed By:
Medtox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
Fluticasone 17-Beta-Carboxylic Acid, Urine
Clinical Information: Inhaled corticosteroids are the single most effective therapy for adult patients
with asthma. Even low doses of inhaled corticosteroids have been shown to reduce mortality related to
asthma. The September 2007 issue of Pediatrics reported that "Verification of [asthma] treatment
adherence by objective measures remains necessary."(1) In this pediatric asthma adherence study, the 104
asthmatic children and their parents grossly overestimated their medication adherence. Over 1 of 3
responses reported full compliance to medications when no medications had been taken. Over 46% of
individuals exaggerated their adherence by at least 25%. The authors concluded that "Under the best of
conditions in this study, accuracy of self-report was insufficient to provide a stand-alone measure of
adherence."(1,2) Fluticasone propionate (FP) is an inhaled corticosteroid with anti-inflammatory and
immunosuppressive properties commonly used for the treatment of asthma, airway inflammation, and
allergic rhinitis. FP is typically well tolerated and has a low risk for adverse systemic effects when utilized
at recommended therapeutic doses. However, noncompliance with recommended FP therapy may result in
poorly controlled asthma or misinterpretation of the patient's therapeutic responsiveness. Patients with
excessive exposure to FP may present with clinical features of Cushing syndrome, but with evidence of
hypothalamus-pituitary-adrenal axis suppression, including suppressed cortisol levels. Conversely, a
patient not administering the drug as recommended may have their therapeutic responsiveness interpreted,
in error by the patient or clinician, as steroid-resistance. FP has low oral bioavailability and high hepatic
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 760